Texas State has officially initiated clinical studies to find out the effects of active compounds in psychedelics such as psilocybin in the treatment of post-traumatic stress disorder (PTSD).
The clinical studies have been authorized in a written legislation by Brownsville Representative Alex Dominguez. The legislation was passed during the last session and signed by Texas State Governor Greg Abbott.
The clinical studies will be seeking to examine the potential benefits of psychedelics compounds such as MDMA, Ketamine, LSD, DMT, Mescaline and psilocybin when used as a therapy for military veterans suffering from post-traumatic stress disorder.
The research is being carried out at the V-A hospital and Baylor College of Medicine in Houston in collaboration with the state Health and Human Services Commission.
This initiative is aiming at having psychedelics therapies used in place of prescribed antidepressant and anti-anxiety drugs which come with heavy side effects.
Various studies have shown that psychedelics compounds are equally effective as antidepressant drugs in treating PTDS, depression and other mental illnesses.